Back to
BLACKROCK ADVISORS LLC
NBIX
Showing 0 of 10 quarters
Position history for
BLACKROCK ADVISORS LLC's holdings in NEUROCRINE BIOSCIENCES INC
As of its last 13F, for Q4 2016, BlackRock Advisors held 616,972 shares of NBIX (Neurocrine Biosciences), worth $23.9M. It reduced the position by 326,218 shares (-34.6%) from Q3 2016. BlackRock Advisors held NBIX from Q3 2014 to Q4 2016, across 10 quarterly 13F filings.
Current Value
—
Current Shares
—
Total Value Change
$0
Total Shares Change
0
No position history available for this security.